drugset / Trial / NCT07244874
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Phase 2
Not yet recruiting
41 enrolled
Tianjin Medical University Cancer Institute and Hospital
Southwest Hospital, China · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).
Timeline
- Start
- 2025-12-01
- Primary completion
- 2028-01-30
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 5 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |